Evidence map›Paper›PMID 40057764›Full record

ArticleCell communication and signaling : CCS2025

Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML.

Yulun Zhong, Rou Zhang, Lingzi Lu, Huijian Tan, Yuyu You, Yang Mao, Yanqiu Yuan

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yulun ZhongSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Rou ZhangSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Lingzi LuSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Huijian TanSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Yuyu YouSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China. youyy8@mail.sysu.edu.cn.
Yang MaoSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China. maoyang3@mail.sysu.edu.cn.
Yanqiu YuanSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China. yuanyq8@mail.sysu.edu.cn.

Funding

Guangdong Provincial Key Laboratory of Drug Nonclinical Evaluation and Research 2023B1212070029National Key Research and Development Program, Ministry of Science and Technology of China 2021YFA1200903the National Natural Science Foundation of China 32001044
6 · The paper itself

Abstract

backgroundProtein arginine methylations are crucial post-translational modifications (PTMs) in eukaryotes, playing a significant regulatory role in diverse biological processes. Here, we present our investigation into the detailed arginine methylation pattern of the C-terminal RG-rich region of METTL14, a key component of the m6A RNA methylation machinery, and its functional implications in biology and disease.

methodsUsing ETD-based mass spectrometry and in vitro enzyme reactions, we uncover a specific arginine methylation pattern on METTL14. RNA methyltransferase activity assays were used to assess the impact of sDMA on METTL3:METTL14 complex activity. RNA immunoprecipitation was used to evaluate mRNA-m6A reader interactions. MeRIP-seq analysis was used to study the genome-wide effect of METTL14 sDMA on m6A modification in acute myeloid leukemia cells.

resultsWe demonstrate that PRMT5 catalyzes the site-specific symmetric dimethylation at R425 and R445 within the extensively methylated RGG/RG motifs of METTL14. We show a positive regulatory role of symmetric dimethylarginines (sDMA) in the catalytic efficiency of the METTL3:METTL14 complex and m6A-specific gene expression in HEK293T and acute myeloid leukemia cells, potentially through the action of m6A reader protein YTHDF1. In addition, the combined inhibition of METTL3 and PRMT5 further reduces the expression of several m6A substrate genes essential for AML proliferation, suggesting a potential therapeutic strategy for AML treatment.

conclusionsThe study confirms the coexistence of sDMA and aDMA modifications on METTL14's RGG/RG motifs, with sDMA at R425 and R445 enhancing METTL3:METTL14's catalytic efficacy and regulating gene expression through m6A deposition in cancer cells.

Indexed as

ArginineLeukemia, Myeloid, AcuteMethyltransferasesAdenosineAmino Acid MotifsCell Line, TumorHEK293 CellsHumansMethylationProtein-Arginine N-MethyltransferasesProtein Processing, Post-TranslationalAdenosineArginineMethyltransferasesMETTL14 protein, humanMETTL3 protein, humanPRMT5 protein, humanProtein-Arginine N-MethyltransferasesAcute myeloid leukemiaMETTL14N6-methyladenosinePost-translational modificationSymmetric dimethylarginine

Identifiers

PMID40057764
PMCPMC11889898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.